Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Rating of “Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned an average recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $12.42.

Several equities research analysts recently weighed in on CLBT shares. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, March 28th. Lake Street Capital started coverage on shares of Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 price objective for the company. Bank of America upped their price objective on shares of Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Craig Hallum upped their price objective on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, William Blair raised shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th.

Cellebrite DI Price Performance

CLBT stock opened at $10.75 on Thursday. Cellebrite DI has a 1-year low of $5.22 and a 1-year high of $12.50. The firm has a fifty day moving average price of $11.27 and a two-hundred day moving average price of $9.39. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -25.00, a PEG ratio of 1.91 and a beta of 1.53.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. The company had revenue of $93.01 million during the quarter, compared to the consensus estimate of $85.43 million. As a group, analysts expect that Cellebrite DI will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC boosted its position in shares of Cellebrite DI by 75.0% in the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after acquiring an additional 1,500 shares during the period. Citigroup Inc. raised its stake in shares of Cellebrite DI by 4.7% in the third quarter. Citigroup Inc. now owns 36,622 shares of the company’s stock valued at $280,000 after purchasing an additional 1,648 shares in the last quarter. Barclays PLC raised its stake in shares of Cellebrite DI by 14.5% in the third quarter. Barclays PLC now owns 15,608 shares of the company’s stock valued at $119,000 after purchasing an additional 1,982 shares in the last quarter. Quarry LP acquired a new position in shares of Cellebrite DI in the fourth quarter valued at $36,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Cellebrite DI by 44.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,091 shares of the company’s stock valued at $115,000 after purchasing an additional 4,672 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.